Prakash Sunil, Pande Dwarika Prasad, Sharma Susham, Sharma Dineshwar, Bal Chandra Shekhar, Kulkarni Hrishikesh
Division, Northern Railway Central Hospital, New Delhi, India.
J Ren Nutr. 2004 Apr;14(2):89-96. doi: 10.1053/j.jrn.2004.01.008.
To assess whether a ketodiet, a combination of ketoanalogs of essential amino acids (KAs) and a very low-protein diet, retards progression of chronic renal failure and maintains nutritional status.
A prospective, randomized, double-blind, placebo-controlled trial.
Nephrology outpatient department in Northern Railways Central Hospital, New Delhi, India.
Thirty-four patients in predialytic stages of chronic renal failure (CRF), randomized to 2 comparable groups in terms of age, sex distribution, blood pressure control, etiology, use of angiotensin converting enzyme inhibitors, serum creatinine, glomerular filtration rate (GFR), and body mass index (BMI).
Subjects randomly received either 0.6 g/kg/d protein plus placebo (n = 16) or 0.3 g/kg/d protein plus tablets of KAs (Ketosteril; Fresenius Kabi, Germany) (n = 18) for 9 months. A dietician administered the diet as well as the KAs or the placebo to the patients.
Changes in GFR and renal and nutritional parameters were measured.
Mean (+/- SD) GFR measured by the 99mTc-DTPA (99 m technetium diethylenetri-aminepenta-aceticacid) plasma sample method was unchanged in the ketodiet group: 28.1 +/- 8.8 (before) and 27.6 +/- 10.1 mL/min/1.73 m2 (after the study) (P =.72). However, it significantly decreased from 28.6 +/- 17.6 to 22.5 +/- 15.9 mL/min/1.73 m2 in the placebo group (P =.015). Serum creatinine before and after the study in the ketodiet group was 2.26 +/- 1.03 mg/dL and 2.07 +/- 0.8 mg/dL (P =.90) and in the placebo group was 2.37 +/- 0.85 and 3.52 +/- 2.9 mg/dL (P =.066), respectively. In both groups the mean BMI did not change from 25.4 +/- 4.2 to 24.5 +/- 4.2 kg/m2 (P =.46) for ketodiet and from 25.0 +/- 6.8 to 23.9 +/- 4.1 kg/m2 (P =.39) for the placebo group. Serum total proteins decreased significantly (P =.038) in the placebo group, and serum albumin showed a trend (P =.061) toward reduction, whereas both of these parameters were maintained in the ketodiet group.
Over a 9-month period, very low-protein diet supplemented with ketoanalogs helped CRF patients to preserve GFR and maintain BMI. KAs were safe and efficacious in retarding the progression of renal failure and preserving the nutritional status of CRF patients.
评估酮饮食(必需氨基酸酮类似物[KAs]与极低蛋白饮食的组合)是否能延缓慢性肾衰竭的进展并维持营养状况。
一项前瞻性、随机、双盲、安慰剂对照试验。
印度新德里北方铁路中心医院肾病门诊。
34例慢性肾衰竭(CRF)透析前阶段的患者,根据年龄、性别分布、血压控制、病因、血管紧张素转换酶抑制剂的使用、血清肌酐、肾小球滤过率(GFR)和体重指数(BMI)随机分为2个可比组。
受试者随机接受0.6 g/kg/d蛋白质加安慰剂(n = 16)或0.3 g/kg/d蛋白质加KAs片剂(Ketosteril;德国费森尤斯卡比公司)(n = 18),为期9个月。由一名营养师为患者提供饮食以及KAs或安慰剂。
测量GFR以及肾脏和营养参数的变化。
采用99mTc - DTPA(99m锝二乙三胺五乙酸)血浆样本法测量,酮饮食组的平均(±标准差)GFR未改变:研究前为28.1±8.8,研究后为27.6±10.1 mL/min/1.73 m²(P = 0.72)。然而,安慰剂组的GFR从28.6±17.6显著降至22.5±15.9 mL/min/1.73 m²(P = 0.015)。酮饮食组研究前后的血清肌酐分别为2.26±1.03 mg/dL和2.07±0.8 mg/dL(P = 0.90),安慰剂组分别为2.37±0.85和3.52±2.9 mg/dL(P = 0.066)。两组的平均BMI均未改变,酮饮食组从25.4±4.2降至24.5±4.2 kg/m²(P = 0.46),安慰剂组从25.0±6.8降至23.9±4.1 kg/m²(P = 0.39)。安慰剂组血清总蛋白显著降低(P = 0.038),血清白蛋白有降低趋势(P = 0.061),而酮饮食组这两个参数均得以维持。
在9个月的时间里,补充酮类似物的极低蛋白饮食有助于CRF患者维持GFR并保持BMI。KAs在延缓肾衰竭进展和维持CRF患者营养状况方面安全有效。